Please ensure Javascript is enabled for purposes of website accessibility

Neuralstem narrows loss in past year

Neuralstem Inc., of Rockville, which is developing products to treat central nervous system disorders with patented stem cell technology, cut its net loss in 2012 to $10.1 million, or 17 cents per share, less than the loss of $12.5 million, or 26 cents per share, that the biotherapeutic company reported for the full year of 2011.

Revenue in 2012 was $407,708, compared to $390,625 for the prior year. (The company did not break down its earnings and revenue for the latest quarter.)

Analysts surveyed by Thompson Reuters on average expected the company to report a loss of 18 cents per share on revenue of $540,000.